Abatacept for the treatment of myositis-associated interstitial lung disease
Issued Date
2025-12-01
Resource Type
ISSN
14620324
eISSN
14620332
Scopus ID
2-s2.0-105024450571
Pubmed ID
40272902
Journal Title
Rheumatology
Volume
64
Issue
SI
Start Page
SI156
End Page
SI168
Rights Holder(s)
SCOPUS
Bibliographic Citation
Rheumatology Vol.64 No.SI (2025) , SI156-SI168
Suggested Citation
Aggarwal R., Pongtarakulpanit N., Sullivan D.I., Moghadam-Kia S., Bae S.S., Wilkerson J., Saygin D., Marder G., Venuturupalli S., Dellaripa P.F., Danoff S.K., Doyle T., Hunninghake G.M., Lee J.S., Fischer A., Falk J., Johnson C., Koontz D., Ascherman D.P., Oddis C.V. Abatacept for the treatment of myositis-associated interstitial lung disease. Rheumatology Vol.64 No.SI (2025) , SI156-SI168. SI168. doi:10.1093/rheumatology/keaf218 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113569
Title
Abatacept for the treatment of myositis-associated interstitial lung disease
Author's Affiliation
Brigham and Women's Hospital
Johns Hopkins University School of Medicine
David Geffen School of Medicine at UCLA
University of Pittsburgh School of Medicine
University of Colorado Anschutz School of Medicine
Rush University Medical Center
Cedars-Sinai Medical Center
Penn Medicine
Bristol Myers Squibb
Northwell Health System
Ramathibodi Hospital
LLC
Johns Hopkins University School of Medicine
David Geffen School of Medicine at UCLA
University of Pittsburgh School of Medicine
University of Colorado Anschutz School of Medicine
Rush University Medical Center
Cedars-Sinai Medical Center
Penn Medicine
Bristol Myers Squibb
Northwell Health System
Ramathibodi Hospital
LLC
Corresponding Author(s)
Other Contributor(s)
Abstract
Objectives This randomized, placebo-controlled pilot trial evaluated the efficacy and safety of abatacept in patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD). Methods Participants with active ASyS-ILD were randomized to receive abatacept (n=9) or placebo (n=11) for 24weeks, followed by a 24-week open-label extension with abatacept for all participants. The primary endpoint was a change in % predicted forced vital capacity (%FVC) from baseline to week 24. Secondary endpoints included changes in the FVC (ml), % predicted diffusing capacity of the lung for carbon monoxide (%DLCO), shortness of breath questionnaire (SOBQ) and pulmonary disease activity on a visual analogue scale (VAS) at weeks 24 and 48. Pre-post baseline analysis of FVC and quantitative image analysis (QIA) of high-resolution computed tomographic scans were performed. Data were analysed using a generalized linear mixed model. The study was not powered for primary or secondary endpoints. Results At week 24, there was no significant difference in the primary endpoint of %FVC change between abatacept and placebo (between treatment difference of −0.35, 95%CI −6.91 to 6.21, P = 0.914) and in all secondary endpoints. However, by week 48, trends favouring abatacept in %FVC, FVC (ml), %DLCO and SOBQ were observed without statistical significance. There was a significant improvement in pulmonary disease activity VAS and pre-post baseline slopes of %FVC and QIA scores in the abatacept arm. Abatacept was generally well tolerated. Conclusion Abatacept did not significantly improve %FVC at 24weeks. However, trends at 48weeks suggest potential benefits, supporting the need for a larger, long-term randomized controlled trial.